Paper
Does amlodipine increase cancer incidence?
Published Jul 10, 2001 · M. Goldstein
Circulation
8
Citations
0
Influential Citations
Abstract
To the Editor: The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)1 amplifies the controversy over calcium antagonists and increased cancer risk.2 In this 36-month, placebo-controlled, randomized trial, the calcium antagonist amlodipine had no effect on the angiographic progression of coronary atherosclerosis or on the risk of major cardiovascular events. In the group assigned to amlodipine, the annualized rates of coronary …
Study Snapshot
Key takeawayAmlodipine does not increase cancer risk or progression of coronary atherosclerosis in this 36-month randomized trial.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Full text analysis coming soon...
References
···
···
···
···
Citations
···
···
···
···